Found: 28
Select item for more details and to access through your institution.
Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study.
- Published in:
- Nephrology Dialysis Transplantation, 2023, v. 38, n. 2, p. 372, doi. 10.1093/ndt/gfac157
- By:
- Publication type:
- Article
Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.
- Published in:
- Nephrology Dialysis Transplantation, 2022, v. 37, n. 7, p. 1261, doi. 10.1093/ndt/gfab336
- By:
- Publication type:
- Article
Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone.
- Published in:
- Nephrology Dialysis Transplantation, 2022, v. 37, n. 6, p. 1014, doi. 10.1093/ndt/gfaa294
- By:
- Publication type:
- Article
Cover Image.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 6, p. 1, doi. 10.1111/dom.15115
- By:
- Publication type:
- Article
Effects of finerenone in people with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baseline.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 6, p. 1512, doi. 10.1111/dom.14999
- By:
- Publication type:
- Article
Front Cover.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 2, p. C1, doi. 10.1111/dom.14960
- By:
- Publication type:
- Article
Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon‐like peptide‐1 receptor agonist use.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 2, p. 407, doi. 10.1111/dom.14883
- By:
- Publication type:
- Article
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP‐1RA treatment: A subgroup analysis from the FIDELIO‐DKD trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 1, p. 125, doi. 10.1111/dom.14558
- By:
- Publication type:
- Article
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.
- Published in:
- European Heart Journal, 2022, v. 43, n. 6, p. 474, doi. 10.1093/eurheartj/ehab777
- By:
- Publication type:
- Article
Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Pooled Secondary Analysis.
- Published in:
- JAMA Network Open, 2022, v. 5, n. 10, p. e2236123, doi. 10.1001/jamanetworkopen.2022.36123
- By:
- Publication type:
- Article
Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO‐DKD trial.
- Published in:
- European Journal of Heart Failure, 2022, v. 24, n. 6, p. 996, doi. 10.1002/ejhf.2469
- By:
- Publication type:
- Article
A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease.
- Published in:
- Clinical Kidney Journal, 2023, v. 16, n. 2, p. 293, doi. 10.1093/ckj/sfac234
- By:
- Publication type:
- Article
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Finerenone Dose-Exposure-Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event Analysis.
- Published in:
- Clinical Pharmacokinetics, 2022, v. 61, n. 3, p. 439, doi. 10.1007/s40262-021-01082-2
- By:
- Publication type:
- Article
Population Pharmacokinetic and Exposure-Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Cardiorenal Outcomes with Finerenone in Asian Patients with Chronic Kidney Disease and Type 2 Diabetes: A FIDELIO-DKD post hoc Analysis.
- Published in:
- American Journal of Nephrology, 2023, v. 54, n. 9/10, p. 370, doi. 10.1159/000532102
- By:
- Publication type:
- Article
Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage.
- Published in:
- American Journal of Nephrology, 2021, v. 52, n. 8, p. 642, doi. 10.1159/000516213
- By:
- Publication type:
- Article
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy.
- Published in:
- JAMA: Journal of the American Medical Association, 2015, v. 314, n. 9, p. 884, doi. 10.1001/jama.2015.10081
- By:
- Publication type:
- Article
Erratum. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA<sub>1c</sub> and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care 2022;45:888–897.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis.
- Published in:
- Diabetes Care, 2022, v. 45, n. 12, p. 2991, doi. 10.2337/dc22-0294
- By:
- Publication type:
- Article
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study.
- Published in:
- 2022
- By:
- Publication type:
- journal article
406-P: Efficacy and Safety of Finerenone in Patients with CKD and T2D by GLP-1RA Treatment.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-406-P
- By:
- Publication type:
- Article
405-P: Efficacy and Safety of Finerenone in Patients with CKD and T2D by Baseline Insulin Treatment.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-405-P
- By:
- Publication type:
- Article
189-OR: FIDELIO-DKD Study: Analysis of Effects of Finerenone by Baseline A1C.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-189-OR
- By:
- Publication type:
- Article
14-LB: Finerenone in Patients with CKD and T2D by SGLT2i Treatment: An Analysis of the FIDELIO-DKD Study.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-14-LB
- By:
- Publication type:
- Article